Project Grant R43AI183983
Award Date 8/11/25
Completion Date 1/31/26
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
- This $380,000 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), on August 1, 2025. The purpose of the grant is to develop a bifunctional RNA therapeutic called PS03 to modulate PD-L1 expression on B cells in order to induce exhaustion of diabetogenic T cells and prevent the onset of type 1 diabetes. Preliminary data suggests that systemic administration of PS03 can...
- This $120,255 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the impact of antigen-specific immunotherapy on the differentiation and function of effector T cells in autoimmune diabetic islet transplants. The study aims to determine how inducing tolerance to a hybrid insulin peptide can expand antigen-specific regulatory T cells that suppress autoreactive CD4 and CD8 T...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This Project Grant award, in the amount of $457,877.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The project aims to evaluate the use of soluble lymphocyte activation gene-3 (sLAG-3) and insulin mRNA as potential early biomarkers for detecting the onset of Type 1 diabetes (T1D) and assessing the effectiveness of immunotherapies. Key objectives include using plasma,...
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- The Project Grant award of $429,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to investigate the role of pH in the pathogenesis of Type 1 Diabetes (T1D). The research, conducted by the University of Colorado-Denver, focuses on understanding how changes in acidity levels within insulin-producing cells can lead to the formation of hybrid insulin peptides (HIPs), which may be...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $307,091 Project Grant to Aleutian Therapeutics, Inc. under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The objective of this Phase I research is to develop immune evasive strategies for allogeneic (non-self) cell replacement therapies, specifically by ascertaining the minimal number of genetic edits required to enable human pluripotent stem cells to overcome xenogeneic...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $700,000 Project Grant to SNC Therapeutics, Inc. The grant supports the development of a tolerogenic nanotherapy to delay the onset of Type 1 Diabetes (T1D). The project aims to demonstrate that subcutaneous administration of rapamycin-loaded polymersomes can induce antigen-specific tolerance and delay T1D onset in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $305,855 to Aleutian Therapeutics, Inc. to develop a novel gene editing platform that enables allogeneic pluripotent stem cell (PSC) therapies to evade host immune system recognition. The goal is to overcome key barriers to making PSC-based regenerative therapies, such as those for type 1 diabetes, more...